Last reviewed · How we verify
Carfilzomib Lenalidomide Dexamethasone
This combination therapy kills multiple myeloma cells by inhibiting the proteasome (carfilzomib), modulating cereblon-mediated protein degradation (lenalidomide), and suppressing inflammatory cytokines (dexamethasone).
This combination therapy kills multiple myeloma cells by inhibiting the proteasome (carfilzomib), modulating cereblon-mediated protein degradation (lenalidomide), and suppressing inflammatory cytokines (dexamethasone). Used for Multiple myeloma (newly diagnosed and relapsed/refractory).
At a glance
| Generic name | Carfilzomib Lenalidomide Dexamethasone |
|---|---|
| Also known as | KRd |
| Sponsor | European Myeloma Network B.V. |
| Drug class | Proteasome inhibitor + Immunomodulatory agent + Corticosteroid combination |
| Target | 20S proteasome (carfilzomib); Cereblon/E3 ubiquitin ligase (lenalidomide); Glucocorticoid receptor (dexamethasone) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Carfilzomib is a proteasome inhibitor that prevents degradation of pro-apoptotic proteins, triggering cancer cell death. Lenalidomide is an immunomodulatory drug that enhances T-cell proliferation and redirects cereblon E3 ligase to degrade oncogenic proteins. Dexamethasone is a corticosteroid that reduces inflammation and enhances the anti-myeloma effects of the other agents. Together, they target multiple pathways in myeloma cell survival and proliferation.
Approved indications
- Multiple myeloma (newly diagnosed and relapsed/refractory)
Common side effects
- Thrombocytopenia
- Anemia
- Neutropenia
- Peripheral neuropathy
- Fatigue
- Diarrhea
- Infection
- Hyperglycemia
- Cardiac toxicity
Key clinical trials
- A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma (PHASE2)
- A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (PHASE1, PHASE2)
- MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) (PHASE3)
- A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2) (PHASE3)
- A Study of Daratumumab (PHASE3)
- Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma (PHASE2)
- LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma (PHASE2)
- Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: